ABSTRACT. Following transcatheter arterial chemoembolisation (TACE), the appearances on CT or MR images are largely related to the chemical and ischaemic insults to the portal tract. Understanding the mechanism of TACE-induced changes is essential for radiologists in order to determine the therapeutic effect as well as to distinguish these changes from recurrent tumours. This pictorial review illustrates the haemodynamic and substantial parenchymal changes related to TACE for hepatic malignancy.
Portal venous perfusion is essential for the function and survival of hepatocytes, whereas the hepatic artery primarily supplies the hepatic framework of the portal tract. Almost all hepatic tumours receive their blood supply from the hepatic artery ( Figure 1 ) [1, 2] . Although several therapeutic options have been advocated, transcatheter arterial chemoembolisation (TACE) has been widely used for hypervascular hepatocellular carcinomas (HCCs) as an effective and palliative treatment [3] . Despite technical efforts to achieve highly selective embolisation of the tumour-supplying vessels, small or large insults to the non-tumorous parenchyma are inevitably induced by the embolic materials or procedure itself. In addition to functional problems, the various imaging appearances of the TACE-induced parenchymal injury have presented a challenge when determining the therapeutic effect or distinguishing this parenchymal injury from the viable tumour. In this article, we review the TACE-induced haemodynamic and parenchymal changes and illustrate their CT and MRI features.
Protocols for TACE and follow-up
Our routine protocol for TACE includes the administration of an emulsion consisting of 1-20 ml of iodised oil (lipiodol; Andre-Guerbet, Aulnay-Sous-Bois, France) and 10-50 mg of doxorubicin (Adriamycin; Kyowa Hakko Kogyo, Tokyo, Japan), with the dose depending on the size, extent and vascularity of the tumour. If possible, the emulsion is injected exclusively into the tumour-feeding segmental or subsegmental arterial branches. This is followed by administration of gelatin sponge (Gelfoam; Upjohn, Kalamazoo, MI) fragments [3, 4] . The first follow-up CT is performed three or four weeks after TACE, and further follow-up CT examinations are performed three months and six months after TACE ( Figure 2 ). If there is no evidence of recurrence of HCC in the six months following TACE, a-fetoprotein levels should be checked every three months and follow-up CT should be taken every year. Repeat TACE or radiofrequency ablation is recommended for residual tumour, marginal recurrence, intrahepatic metastases or newly developed lesions with arterial enhancement and venous washout on follow-up CT. MRI is needed for artefacts from dense lipiodol accumulation and arterial hypervascular pseudolesions from perfusion variation, and a technical limitation such as unoptimised arterial phase imaging for follow-up CT. Repeat TACE is performed for the HCC recurrence seen on MRI, and cases with no recurrence require routine follow-up CT examinations.
Bile duct injuries
Bilomas are the most common type of biliary complication after TACE [5] . The incidence of bile duct injury was significantly higher in patients with non-advanced cirrhotic liver, those undergoing highly selective embolisations and those with a history of repeated TACE procedures [6] . In acute-stage bile duct injury, necrosis of the bile ductule followed by rupture may lead to biloma formation, with or without secondary infection, and abscess formation, which may require an urgent drainage procedure (Figures 3 and 4) . Stricture and dilatation of the bile duct are indicative of chronic-stage bile duct injury (Figure 3 ).
Portal vein obliteration
In addition to the direct chemical and ischaemic insults by the embolic agents via the vasa vasorum or periportal capillary plexus, extravasated bile from the disruption of the necrotised bile duct can track along the sheaths of Glisson capsule and result in portal phlebitis and compromised vascular patency [4, 7] . There is also the possibility that the dilated bile duct proximal to the stricture site will gradually compress the adjacent portal vein branches in the injured portal tract (Figures 3-5 ). Gross appearance of large intrahepatic bile duct injury tends to be followed by obliteration of the adjacent portal vein ( Figure 5 ). Bile duct dilatations usually appear within one month after TACE, and most of the portal vein obliteration appears one to six months after TACE [4] .
Acute parenchymal infarct
Owing to the intra-arterially infused chemoembolic materials, the period of stasis of arterial flow depends on the arterial diameter, the development of collateralisation and the total amount and density of embolic materials used. Embolic materials flow into the portal venules through the transplexal route, which leads to obliteration of the portal venules [7] . In the above conditions, the simultaneously decreased arterial and portal venous perfusion results in parenchymal infarction, which appears as a low-density area on all phases of dynamic CT ( Figure 6 ). During the follow-up periods, some arterial inflow can be recovered by arterial recanalisation or collateralisation ( Figure 7 ). Arterial reperfusion of previously infarcted parenchyma can demonstrate inhomogeneous enhancement on arterial phase images. Owing to the decreased attenuation of the infarcted area on pre-contrast and equilibrium-phase images, it can be hard to differentiate the reperfused area from a viable tumour that shows subsequent washout of contrast material. Superparamagnetic iron oxide particle (SPIO) uptake is also decreased in the infarcted parenchyma in the vicinity of the lesion (Figure 8 ).
Arterioportal fistulae
After TACE, chemical or ischaemic injury of the portal tract and direct mechanical injury of the arterial wall by the guide wire or catheter itself can induce the formation of a fistula between small arteries and the portal vein branches alongside [8] . Typically, subcapsular, wedgeshaped or irregular arterial phase enhancement during dynamic CT or MRI could be regarded as an arterioportal fistula (APF) (Figures 9 and 10 ). Owing to the traumatic or acute inflammatory nature of this injury, most traumatic APFs would disappear on the serial follow-up imaging studies (Figure 9 ). In the advanced cirrhotic liver, differential diagnosis of APF from recurrent HCC is sometimes difficult because of the parenchymal distortion and inhomogeneous attenuation of the background liver on delayed-phase images (Figure 11 ). MRI using Kupffer cell agent (SPIO) is helpful for excluding a true tumour from an acute APF-induced arterioportal shunt that shows normal SPIO uptake (Figure 11 ) [9] .
Parenchymal atrophy
Parenchymal atrophy occurs because of decreased portal venous perfusion following acute or gradual vascular compromise caused by bile duct injury, arterial vasculitis, portal phlebitis and/or passive compression ( Figures 5, 6 , 8 and 10) [4, 10] . Depending on the extent of involvement, TACE-induced parenchymal atrophy in the cirrhotic liver, in which portal venous inflow is already decreased by portal hypertension, may deteriorate liver function. Yu et al [4] reported the mean time between TACE and the appearance of atrophic changes as 20 weeks.
Conclusions
After TACE, the appearances on CT or MRI are largely related to the chemical and ischemic insults to the portal tract. The mechanism and imaging findings of TACEinduced changes should be familiar to radiologists, so that they can determinate the therapeutic effect as well as distinguish such changes from a recurrent tumour. Serial follow-up is still essential and selective application of liver-specific contrast-enhanced MRI is recommended for accurate assessment of relevant conditions.
